Authors’ Reply to Suhas et al.: Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation”

被引：0

作者：

Georgios Schoretsanitis

Maxim Kuzin

John M. Kane

Christoph Hiemke

Michael Paulzen

Ekkehard Haen

机构：

[1] The Zucker Hillside Hospital,Clienia Schloessli

[2] Psychiatry Research,Department of Psychiatry and Molecular Medicine

[3] Northwell Health,Center for Psychiatric Neuroscience

[4] Behavioral Health Pavilion,Department of Psychiatry and Psychotherapy and Institute of Clinical Chemistry and Laboratory Medicine

[5] University Hospital of Psychiatry Zurich,Department of Psychiatry, Psychotherapy and Psychosomatics

[6] Private Psychiatric Hospital and Academic Teaching Hospital of the University of Zurich,Department of Psychiatry and Psychotherapy, Clinical Pharmacology

[7] Zucker School of Medicine at Hofstra/Northwell,Department of Pharmacology and Toxicology

[8] The Feinstein Institute for Medical Research,undefined

[9] University Medical Center of Mainz,undefined

[10] Alexianer Hospital Aachen,undefined

[11] RWTH Aachen University,undefined

[12] JARA-Translational Brain Medicine,undefined

[13] University of Regensburg,undefined

[14] University of Regensburg,undefined

来源：

Clinical Pharmacokinetics | 2021年 / 60卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1077 / 1079

页数：2

共 50 条

[1] Authors' Reply to Suhas et al.: Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation"
Schoretsanitis, Georgios
Kuzin, Maxim
Kane, John M.
Hiemke, Christoph
Paulzen, Michael
Haen, Ekkehard
CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1077 - 1079
[2] Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation"
Suhas, Satish
Kumar, Vijay
Damodharan, Dinakaran
Sharma, Priyamvada
Rao, Naren P.
Varambally, Shivarama
Venkatasubramanian, Ganesan
Murthy, Pratima
Gangadhar, Bangalore N.
CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1073 - 1075
[3] Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation”
Satish Suhas
Vijay Kumar
Dinakaran Damodharan
Priyamvada Sharma
Naren P. Rao
Shivarama Varambally
Ganesan Venkatasubramanian
Pratima Murthy
Bangalore N. Gangadhar
Clinical Pharmacokinetics, 2021, 60 : 1073 - 1075
[4] Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation
Schoretsanitis, Georgios
Kuzin, Maxim
Kane, John M.
Hiemke, Christoph
Paulzen, Michael
Haen, Ekkehard
CLINICAL PHARMACOKINETICS, 2021, 60 (03) : 329 - 335
[5] Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation
Georgios Schoretsanitis
Maxim Kuzin
John M. Kane
Christoph Hiemke
Michael Paulzen
Ekkehard Haen
Clinical Pharmacokinetics, 2021, 60 : 329 - 335
[6] Comment: unanticipated plasma concentrations in two clozapine-treated patients
Lu, ML
Lang, HY
Chang, WH
ANNALS OF PHARMACOTHERAPY, 2001, 35 (12) : 1675 - 1676
[7] Unanticipated plasma concentrations in two clozapine-treated patients
Alfaro, CL
McClure, RK
Vertrees, JE
Benavides, R
ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1028 - 1031
[8] Authors reply to comment on Hayman et al. "elevated osmol gaps in patients with alcoholic ketoacidosis"
Hayman, Chelsea V.
Pires, Kyle D.
Cohen, Emily T.
Biary, Rana
Su, Mark K.
Hoffman, Robert S.
CLINICAL TOXICOLOGY, 2025, 63 (01) : 70 - 71
[9] Authors' reply to the comment by Alam et al.
Kjelgaard Pedersen, L.
Fisker, L. Y. V.
Roelfing, J. D.
Ahlburg, P.
Veien, M.
Vase, L.
Moller-Madsen, B.
EUROPEAN JOURNAL OF PAIN, 2024, 28 (03) : 508 - 509
[10] Authors reply to the comment of Backryd et al.
Haeuser, Winfried
Morlion, Bart
EUROPEAN JOURNAL OF PAIN, 2022, 26 (05) : 1176 - 1176

← 1 2 3 4 5 →